Oncternal Therapeutics, Inc. (NASDAQ:ONCT) disclosed a significant reduction in its workforce and changes to executive roles, according to a recent 8-K SEC filing. The San Diego-based pharmaceutical company, known for its focus on cancer treatments, has decided to reduce its staff count, with the majority of related charges expected to be recognized in the fourth quarter of 2024.
The company's board of directors unanimously approved the workforce reduction on Wednesday, November 13, 2024. The action will be effective on or before Monday, December 2, 2024, leaving only four employees on a part-time basis to aid in the exploration of strategic alternatives.
Oncternal estimates that it will incur approximately $2.4 million in charges primarily related to severance payments, benefits, and related termination costs.
In conjunction with the downsizing, two key executives, James B. Breitmeyer, M.D., Ph.D., and Richard G. Vincent, will transition to part-time status, reducing their duties by 50% starting December 2, 2024. Both will receive severance payments and continued health benefits as per their employment agreements.
Additional charges or cash expenditures not currently anticipated may arise due to unforeseen events during the implementation of the workforce reduction.
This news comes amid a challenging time for Oncternal, as it evaluates its future direction in the pharmaceutical industry. The information in this article is based on statements from the press release.
In other recent news, Oncternal Therapeutics reported positive results from its Phase 1/2 study of ONCT-534 for treating metastatic Castration-Resistant Prostate Cancer (mCRPC). The study demonstrated that the drug was well tolerated, with a notable patient showing a 50% reduction in PSA after four weeks on a 300 mg dose.
However, the company decided to discontinue the ONCT-534-101 clinical trial due to the current biotechnology environment.
Oncternal has also discontinued clinical trials for ONCT-534 and ONCT-808, treatments for metastatic castration-resistant cancer and aggressive B-cell lymphoma respectively. As part of these recent developments, the company is now investigating strategic alternatives to maximize shareholder value, which may include asset sales, licensing, mergers, or other business combinations.
During this process, all product development activities will be halted and further cost reductions will be implemented. These changes also include the departure of Chief Medical (TASE:PMCN) Officer Dr. Salim Yazji, effective October 1, 2024.
InvestingPro Insights
The recent workforce reduction and executive role changes at Oncternal Therapeutics (NASDAQ:ONCT) reflect the company's challenging financial position, as highlighted by several InvestingPro metrics and tips.
According to InvestingPro data, Oncternal's market capitalization stands at a mere $3.29 million, indicating its small-cap status. The company's revenue for the last twelve months as of Q3 2024 was $2.16 million, with a substantial revenue growth of 227.92% over the same period. However, this growth hasn't translated into profitability, as evidenced by the negative gross profit of -$6.51 million and an alarming operating income margin of -2040.52%.
InvestingPro Tips reveal that Oncternal "holds more cash than debt on its balance sheet" and "liquid assets exceed short term obligations," which could provide some financial flexibility as the company navigates its restructuring. However, the tip that the company "suffers from weak gross profit margins" aligns with the reported financial data and explains the need for cost-cutting measures.
The stock's performance has been notably poor, with InvestingPro reporting a significant price decline of 86.79% over the past six months and 81.41% over the past year. This downward trend underscores the challenges facing the company and the market's reaction to its financial struggles.
For investors seeking a more comprehensive analysis, InvestingPro offers 13 additional tips for Oncternal Therapeutics, providing deeper insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.